期刊
ATHEROSCLEROSIS
卷 281, 期 -, 页码 189-197出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2018.10.006
关键词
Atherosclerosis; Inflammation; Immune cells; Epigenetic; Histone modification; DNA methylation; Epigenetic inhibitors
资金
- European Union's Horizon 2020 research and innovation program [667837]
- H2020 Societal Challenges Programme [667837] Funding Source: H2020 Societal Challenges Programme
Notwithstanding the intense efforts into the understanding and prevention of cardiovascular disease (CVD), its complex pathology remains the leading cause of mortality worldwide. The pivotal role of epigenetic changes in the control of gene expression has been profiled in several diseases, such as cancer and inflammatory disorders. In the last decade, increasing evidence has also linked aberrant epigenetic modulation as a contributor to CVD development. Differential profiles of DNA methylation, histone methylation and acetylation have consistently been observed in tissues and cells (comprising the aortic lesions, vascular endothelium and monocytes) from patients with CVD. This highlights the therapeutic potential of epigenetic drugs for cardiovascular treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据